Abstract Psoriasis affects over 125 million people globally. Biologics targeting the IL-17/IL-17RA axis are effective but require systemic administration, are costly, and are unsuitable for some patients. Developing topical small-molecule alternatives requires a better understanding of how IL-17 receptor A (IL17RA) is regulated in keratinocytes, the principal effector cells of psoriatic lesions.
Ryan Mcclure
Get in touch with Ryan
Contact Ryan, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack